EUVIMEDEUVIMED entdecken
Open Access

Clinical- and Cost-Effectiveness of Liver Disease Staging in Hepatitis C Virus Infection: A Microsimulation Study

Rachel L Epstein iD, Sarah Munroe iD, Lynn E Taylor, Patrick R Duryea, Benjamin Buzzee, Tannishtha Pramanick, Jordan J Feld, Dimitri Baptiste, Matthew Carroll, Laurent Castera, Richard K Sterling, Aurielle Thomas und 2 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciae485 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Rachel L Epstein und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Section of Infectious Diseases, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Hepatitis C, Chronic, Liver Cirrhosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Catherine and Patrick Weldon Donaghue Foundation Greater Value Portfolio Grant, NIDA NIH HHS, Charles A. King Trust Postdoctoral Research Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Liver disease assessment is a key aspect of chronic hepatitis C virus (HCV) infection pre-treatment evaluation but guidelines differ on the optimal testing modality given trade-offs in availability and accuracy. We compared clinical outcomes and cost-effectiveness of common fibrosis staging strategies.

Methods

We simulated adults with chronic HCV receiving care at US health centers through a lifetime microsimulation across five strategies: (1) no staging or treatment (comparator), (2) indirect serum biomarker testing (Fibrosis-4 index [FIB-4]) only, (3) transient elastography (TE) only, (4) staged approach: FIB-4 for all, TE only for intermediate FIB-4 scores (1.45–3.25), and (5) both tests for all. Outcomes included infections cured, cirrhosis cases, liver-related deaths, costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). We used literature-informed loss to follow-up (LTFU) rates and 2021 Medicaid perspective and costs.

Results

FIB-4 alone generated the best clinical outcomes: 87.7% cured, 8.7% developed cirrhosis, and 4.6% had liver-related deaths. TE strategies cured 58.5%–76.6%, 16.8%–29.4% developed cirrhosis, and 11.6%–22.6% had liver-related deaths. All TE strategies yielded worse clinical outcomes at higher costs per QALY than FIB-4 only, which had an ICER of $12 869 per QALY gained compared with no staging or treatment. LTFU drove these findings: TE strategies were only cost-effective with no LTFU. In a point-of-care HCV test-and-treat scenario, treatment without any staging was most clinically and cost-effective.

Conclusions

FIB-4 staging alone resulted in optimal clinical outcomes and was cost-effective. Treatment for chronic HCV should not be delayed while awaiting fibrosis staging with TE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisHepatitis C, ChronicLiver CirrhosisHumansMaleMiddle AgedFemaleAdultQuality-Adjusted Life YearsElasticity Imaging TechniquesSeverity of Illness IndexBiomarkersUnited StatesComputer SimulationHepacivirus

Stichwörter der Autor:innen

APRIFIB-4elastographyguidelineshepatitis C

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Medicine, Section of Infectious Diseases, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
  • Department of Pediatrics, Section of Infectious Diseases, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
  • Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts, USA.
  • Department of Pharmacy Practice and Clinical Research, University of Rhode Island, Kingston, Rhode Island, USA.
  • Department of Primary Care, HealthFirst Family Care Center Inc., Fall River, Massachusetts, USA.
  • Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Rachel L Epstein, Sarah Munroe

Förderung

  • Catherine and Patrick Weldon Donaghue Foundation Greater Value Portfolio Grant
  • NIDA NIH HHS
  • Charles A. King Trust Postdoctoral Research Fellowship
  • NIAID NIH HHS
  • Boston University
  • Department of Medicine Career Investment
  • Chobanian & Avedisian School of Medicine
  • Providence/Boston Center for AIDS Research

Zitieren

APA

Epstein, R. L., Munroe, S., Taylor, L. E., Duryea, P. R., Buzzee, B., Pramanick, T., Feld, J. J., Baptiste, D., Carroll, M., Castera, L., Sterling, R. K., Thomas, A., Chan, P. A., & Linas, B. P. (2025). Clinical- and Cost-Effectiveness of Liver Disease Staging in Hepatitis C Virus Infection: A Microsimulation Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae485

Vancouver

Epstein RL, Munroe S, Taylor LE, Duryea PR, Buzzee B, Pramanick T, et al. Clinical- and Cost-Effectiveness of Liver Disease Staging in Hepatitis C Virus Infection: A Microsimulation Study. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae485

BibTeX
@article{Epstein2025,
  author = {Epstein, Rachel L and Munroe, Sarah and Taylor, Lynn E and Duryea, Patrick R and Buzzee, Benjamin and Pramanick, Tannishtha and Feld, Jordan J and Baptiste, Dimitri and Carroll, Matthew and Castera, Laurent and Sterling, Richard K and Thomas, Aurielle and Chan, Philip A and Linas, Benjamin P},
  title = {Clinical- and Cost-Effectiveness of Liver Disease Staging in Hepatitis C Virus Infection: A Microsimulation Study},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciae485}
}
Kostenlos starten →